Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer - A cost-effective addition to the treatment sequence.

被引：0
|
作者：
Cameron, D. A.
Camidge, D. R.
Gait, C.
Hirsch, M.
机构：
[1] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[2] Mapi Values, Cheshire, England
[3] AstraZeneca, Macclesfield, Cheshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：S231 / S232
页数：2
相关论文
共 50 条
  • [21] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [22] Tolerability of Therapies Recommended for the Treatment of Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
    Ohno, Shinji
    CLINICAL BREAST CANCER, 2016, 16 (04) : 238 - 246
  • [23] The therapeutic role of fulvestrant in the management of patients with hormone receptor-positive breast cancer
    Ciruelos, Eva
    Pascual, Tomas
    Arroyo Vozmediano, Maria Luisa
    Blanco, Marta
    Manso, Luis
    Parrilla, Lucia
    Munoz, Cesar
    Vega, Estela
    Jackelin Calderon, Monica
    Sancho, Blanca
    Cortes-Funes, Hernan
    BREAST, 2014, 23 (03): : 201 - 208
  • [24] Treatment of Early-Stage Hormone Receptor-Positive Breast Cancer
    Rugo, Hope S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 596 - 599
  • [25] Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer
    Sebastian, William
    Forchette, Lauren
    Donoughe, Kelsey
    Lun, Yibei
    Verma, Anisha
    Liu, Tuoen
    CANCERS, 2023, 15 (04)
  • [26] A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer
    Cleator, Susan J.
    Ahamed, Eliyaz
    Coombes, R. Charles
    Palmieri, Carlo
    CLINICAL BREAST CANCER, 2009, 9 : S6 - S17
  • [27] COST EFFECTIVENESS OF FULVESTRANT 500 MG IN ENDOCRINE THERAPY-NAIVE WOMEN WITH HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN THE UK
    Livings, C.
    Jones, N.
    Bertranou, E.
    Large, S.
    Phelps, H.
    Ekman, M.
    Telford, C.
    VALUE IN HEALTH, 2017, 20 (09) : A435 - A435
  • [28] ECONOMIC EVALUATION OF FULVESTRANT (FASLODEX®) AS AN ADDITIONAL ENDOCRINE STEP IN THE TREATMENT SEQUENCE FOR HORMONE-RECEPTOR POSITIVE ADVANCED AND METASTATIC BREAST CANCER IN ISRAEL
    Greenberg, D.
    Rabinovich, M.
    Hirsch, M.
    VALUE IN HEALTH, 2009, 12 (03) : A46 - A46
  • [29] Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer
    McCormack, Peter
    Sapunar, Francisco
    CLINICAL BREAST CANCER, 2008, 8 (04) : 347 - 351
  • [30] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
12345